- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06426303
외상, 염증 및 뇌 기능의 성별 차이와 알코올 사용 장애의 치료 효능에 대한 의미 (ABSTAIN)
The goal of this clinical trial is to identify sex-specific biomarkers that confer greater susceptibility for Alcohol Use Disorder (AUD) and differentiate how treatment response varies by sex in people with Alcohol Use Disorder.
The main questions it aims to answer are:
- How does trauma affect emotion regulation, inflammation, and limbic function, and what are the sex-dependent effects of NTX (Naltrexone) on these aspects?
- What is the mechanism of Naltrexone (NTX), and how does it potentially moderate reductions in alcohol use through changes in or interactions between emotion regulation, inflammation, or limbic system function?
Participants will
- Be consented and will undergo comprehensive screening for eligibility criteria
- Complete behavioral assessments and neuropsychological assessments, as well as neurocognitive assessments and neuroimaging measures
- Provide urine samples for a urine drug screen (UDS) and urine pregnancy test (for women), and have blood and a cheek swab collected and stored in the repository
- Take a study drug once daily for 12 weeks and track drug usage and effects in a study journal
- Undergo weekly assessment calls and bi-weekly medical follow-up safety exams
Researchers will compare naltrexone to placebo in AUD to see if naltrexone is effective in reducing alcohol cravings and promoting abstinence.
Researchers will also compare baseline measures between AUD and Healthy Controls.
연구 개요
상세 설명
A twelve-week randomized placebo-controlled trial of naltrexone (NTX) will be conducted in one hundred people with alcohol use disorder (AUD), fifty of which will be women. Fifty healthy participants will serve as controls for baseline measures. We will use validated measures to comprehensively assess trauma exposure including: military sexual trauma (MST), physical or sexual assault, combat exposure, intimate partner violence, and other traumatic events. Emotion regulation will be assessed with the Cognitive Emotion Regulation questionnaire and Difficulty in Emotion Regulation scale. Functional magnetic resonance imaging at rest and during an emotion regulation task will assess limbic system connectivity and reactivity. Inflammation will be indexed with a multiplex panel assay of peripheral inflammatory markers. Days of alcohol use and average weekly standard drinks will be assessed at each time-point.
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: Jazryn Nagum
- 전화번호: 503-721-7964
- 이메일: vhaporhoffmanlab@va.gov
연구 장소
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- 모병
- VA Portland Health Care System
-
연락하다:
- Jazryn Nagum
- 전화번호: 503-721-7964
- 이메일: vhaporhoffmanlab@va.gov
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 18-60 years old
- Veteran enrolled in VHA healthcare
Alcohol Group:
- must meet diagnosis for recent alcohol-use disorder (DSM-V)
- willing to return for follow-up visits and can participate for 12-weeks
Control Group:
- must not meet DSM-V criteria for a use disorder other than nicotine
Exclusion Criteria:
- Clinically significant neurological, endocrine, hepatic, or systemic disease that would compromise safe participation or confound outcomes
- Left-handedness
- Axis-1 psychiatric diagnoses other than anxiety, depression or post-traumatic stress disorder
- Recreational or prescriptive use of psychotropic medications
- Recreational or prescriptive use of opioid medications or have a past or current history of abuse or dependence on opioids
- MRI contraindications (e.g. metal in body)
- Positive urine drug screen, except for nicotine and marijuana, on test days
- Women who are pregnant or breastfeeding
- Participants on hormonal therapy or treatments other than pregnancy contraceptives
- Autoimmune or neurodegenerative diseases that present with neuroinflammation (multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's, Parkinson's)
- Current participation in an investigational drug study
- Alcohol group: < 5 days and > 3 weeks of abstinence from alcohol
- Alcohol group: Liver disease requiring medication or medical treatment, and/or aspartate or alanine aminotransferase levels greater than 3 times the upper limit of normal, gastrointestinal or renal disease that would significantly impair absorption, metabolism or excretion of study drug, or require medical treatment.
- Non-english speaker
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Alcohol Use Disorder (AUD)
Drug: Naltrexone Half of the study participants with AUD will take an oral tablet of 50 mg naltrexone once daily for one week followed by 11 weeks of 100 mg naltrexone orally, once daily. Drug: Placebo oral tablet The other half of study participants will receive an identical looking placebo in tablet form and take the medication using an identical schedule as the real drug. Drug type will be randomized. |
12-week randomized double blinded placebo-controlled drug trial titrating drug/placebo dose after 1 week.
다른 이름들:
|
|
간섭 없음: Healthy Controls
Baseline measures will be taken but controls will not continue to the drug trial. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from baseline in alcohol use (number of drinking days, amount used per day)
기간: Baseline and Week 12
|
Drinking days and average number of weekly standard drinks will be measured at baseline and at follow-up |
Baseline and Week 12
|
|
Changes from baseline in peripheral immune biomarkers associated with inflammation
기간: Baseline and Week 12
|
Plasma samples will be analyzed using a customized, high-sensitivity magnetic bead multiplex assay Luminex system. Samples will be prepared and analyzed to measure peripheral immune markers: interleukin (IL)-1-beta, IL-6, IL-10, tumor necrosis factor (TNF)-alpha, brain-derived neurotrophic factor (BDNF), monocyte chemotactic protein (MCP)-1 and neural cell adhesion molecule (NCAM). Intra-and inter-assay coefficients of variation, as indices of within-and between-assay precision, respectively, will be calculated to examine the reliability of cytokine measurements. |
Baseline and Week 12
|
|
Changes in limbic functional connectivity
기간: Baseline and Week 12
|
Resting-state functional magnetic resonance imaging (rs-fMRI) will be used to assess changes in limbic system connectivity. Correlation coefficients of low-frequency oscillations in the fMRI blood oxygenation level dependent (BOLD) signal between regions and between large-scale resting-state networks in the brain will be z-score transformed. A score of 0 indicates no change while higher or lower scores indicate increased or decreased connectivity, respectively. |
Baseline and Week 12
|
|
Changes from baseline in BOLD signal brain activation during an emotion regulation fMRI task
기간: Baseline and Week 12
|
The task will assess emotional reactivity and regulation to negative and stressful images. Each event (cue, neutral-look, negative-look, negative-reappraise and rating scale of negative affect) will be modeled using a canonical hemodynamic response function with a time derivative. The contrasts of interest will be Negative-look vs Neutral-look and Negative-look vs Negative-reappraise. Amygdala BOLD signal estimates will be extracted to calculate percent-change. |
Baseline and Week 12
|
|
Changes from baseline in emotion regulation assessed with the Difficulty in Emotion Regulation Scale (DERS)
기간: Baseline and Week 12
|
DERS is a 36-item self-report questionnaire scored on a 5-point scale from 1 (almost never) to 5 (almost always), with total score ranging from 36 to 180. It measures emotion regulation difficulties across six dimensions: 1. Non-acceptance of emotional responses, 2. Difficulties engaging in goal-directed behavior, 3. Impulse control difficulties, 4. Lack of emotional awareness, 5. Limited access to effective emotion regulation strategies, 6. Lack of emotional clarity. Higher scores suggest greater difficulties in emotion regulation. |
Baseline and Week 12
|
|
Changes from baseline in emotion regulation assessed with the Cognitive Emotion Regulation Questionnaire (CERQ)
기간: Baseline and Week 12
|
CERQ is a 36-item self-report questionnaire that identifies cognitive emotion regulation or cognitive coping strategies used after having experienced negative events or situations. Scores can identify individual strategies to compare with normed scores from various populations. The nine cognitive emotion regulation strategies are measured on a 5-point Likert scale ranging from 1 to 5, with scores being obtained by calculating the mean scores belonging to a particular subscale. Higher subscale scores indicate greater use of a specific cognitive strategy. |
Baseline and Week 12
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from baseline in craving (include craving measures/questionnaires)
기간: Baseline and Week 12
|
The Brief Alcohol Craving Scale, a 10-item self-report assessment of craving, will be used. Participants will be prompted with a statement regarding alcohol cravings and will choose an answer ranging between "strongly disagree" and "strongly agree." |
Baseline and Week 12
|
|
Differences in baseline trauma exposure (composite score)
기간: Baseline and Week 12
|
Department of Veterans Affairs Military Sexual Trauma Screening consists of two questions used nationally within the Veterans Heath Administration (VHA) to screen for MST. Response options are yes, no, or decline to respond. Trauma Assessment for Adults (TAA) is a 17-item self-report on combat exposure, physical or sexual assault, surviving serious accidents and other threatening life events. Life Stressor Checklist-Revised (LSC-R) includes self-report measures relevant to women such as abortion or caregiver duties, in addition to 30 life events related to natural disasters, physical or sexual assault, death of a relative, incarceration and financial hardships. Childhood Maltreatment questionnaire is 70 items in five dimensions: emotional, physical, and sexual abuse, and physical and emotional neglect. A 7-point scale will be used to indicate level of trauma |
Baseline and Week 12
|
|
Change from baseline in neuropsychological testing scores
기간: Baseline and Week 12
|
The Standard Neuropsychological Battery will be used |
Baseline and Week 12
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 25536
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .